Topic: Alpha-synuclein aggregation

Neurodegenerative disorders (NDs) are characterized by a progressive loss of neurons leading to broad symptoms affecting cognition and motor function. Despite extensive research efforts, treatment options remain palliative, and due to increasing incidence of NDs worldwide, novel therapies are necessary. Gene therapy represents an attractive approach for tackling the complex pathology of NDs. CRISPR-mediated gene activation (CRISPRa) encompasses a growing field of biotechnological approaches with exciting implications for gene therapy through upregulation of genetic targets of interest. However

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, following Alzheimer's disease. It is characterized by the degeneration of dopaminergic neurons in the SNpc, resulting in both motor and non-motor symptoms. Current treatments are limited, and PD's molecular basis involves alpha-synuclein aggregation, ubiquitination dysregulation, and oxidative stress. Nicotine, found in tobacco, has been associated with reduced PD risk in epidemiological studies and shown neuroprotective effects in animal models. However, its impact on oxidative stress remains unclear. A study in